Reaction
Anterior Chamber Inflammation reporting signals
As of the last recalculation, Anterior Chamber Inflammation appears in 580 FAERS reports alongside 9 co-occurring drug terms. The strongest observed disproportionality signal is FARICIMAB (PRR 324.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Faricimab | 65 | 324.0 | 326.7 |
| Aflibercept | 117 | 168.3 | 169.0 |
| Ranibizumab | 53 | 78.8 | 78.9 |
| Cefuroxime | 23 | 75.1 | 75.3 |
| Moxifloxacin Hydrochloride | 24 | 44.3 | 44.3 |
| Prednisolone Acetate | 9 | 31.7 | 31.7 |
| Brimonidine Tartrate | 15 | 31.0 | 31.0 |
| Timolol | 9 | 27.1 | 27.2 |
| Itraconazole | 8 | 24.9 | 24.9 |